Angionika s.r.o.
- Address
- Fibichova 586, 252 64 Slany, Czechia
Angionika s.r.o. - Cardiovascular & Lipid Metabolism Research Center
Angionika s.r.o. is a specialized research center dedicated to advancing the understanding and treatment of cardiovascular disease and lipid disorders. The center focuses on evaluating novel therapeutic approaches for patients with dyslipidemia and elevated cardiovascular risk, conducting pivotal trials that assess both efficacy and quality of life outcomes in complex patient populations.
- Advanced lipid-lowering therapies including inclisiran for hypercholesterolemia management
- Cardiovascular outcomes research targeting major adverse cardiac events (MACE) prevention
- Lipoprotein(a) reduction strategies using novel agents like pelacarsen
The center's research portfolio emphasizes precision medicine approaches to LDL-cholesterol and Lp(a) management, examining individualized treatment targets in patients with established cardiovascular disease. Through participation in large-scale multicenter trials, Angionika contributes to the development of therapies aimed at reducing cardiovascular mortality, myocardial infarction, stroke, and the need for urgent coronary revascularization in high-risk populations.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Novartis Pharma AG1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novartis Pharma AG2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 634 other sites in Czechia
Therapeutic Area Benchmark — Czechia
Select a therapeutic area to compare against other sites in Czechia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Czechia
Market Share
Country: Czechia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Angionika s.r.o.
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Long-term Safety and Tolerability Evaluation of Pelacarsen in Patients with Elevated Lipoprotein(a) and Established Atherosclerotic Cardiovascular Disease | Novartis Pharma AG | Phase III | Recruiting | May 2026 | — |
IMP list
lock Showing 1 of 3 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Inclisiran | 1 | Unknown | 2022-04-08 | 2022-04-08 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.